{"nctId":"NCT00523744","briefTitle":"Efficacy and Safety of Valsartan and Amlodipine (Â± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension","startDateStruct":{"date":"2007-07"},"conditions":["Hypertension"],"count":257,"armGroups":[{"label":"Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ","type":"EXPERIMENTAL","interventionNames":["Drug: Amlodipine","Drug: Olmesartan medoxomil","Drug: Amlodipine+valsartan","Drug: Hydrochlorothiazide"]}],"interventions":[{"name":"Amlodipine","otherNames":[]},{"name":"Olmesartan medoxomil","otherNames":[]},{"name":"Amlodipine+valsartan","otherNames":["Exforge"]},{"name":"Hydrochlorothiazide","otherNames":["Sandoz"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Core study:\n\n* Male or female patients (\\>=18 years)\n* Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods\n* Patients with essential hypertension (diastolic blood pressure \\>=100 mmHg and \\<110 mmHg)\n\nInclusion Criteria for Extension:\n\n\\- Patients had to have a msSBP \\>= 140 mmHg and/or msDBP \\>= 90 mmHg at week 8 ie, end of core study.\n\nExclusion Criteria for Core study:\n\n* Severe hypertension (diastolic blood pressure \\>=110 mmHg or systolic blood pressure \\>= 180 mmHg)\n* Pregnant or nursing women\n* Treated hypertensive patients with controlled hypertension under current therapy\n* A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II - IV\n\nExclusion Criteria for Extension:\n\n* prematurely discontinued the core study\n* failed to comply with the core study protocol\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.13","spread":"1.97"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.87","spread":"9.48"}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Pressure During the Core Phase of the Study","description":"Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"9.64"}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Rate During the Core Phase of the Study","description":"Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study","description":"Normalized Blood Pressure was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study","description":"Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 (Week 8) compared to Baseline in Phase 2 (week 4) or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study","description":"The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Pressure During the Extension Phase of the Study","description":"Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Sitting Pulse Rate During the Extension Phase of the Study","description":"Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study","description":"Normalized Blood Pressure was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study","description":"Blood pressure response was defined as msSBP \\< 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 3 compared to Baseline in Phase 3 or a msDBP \\< 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 3 compared to Baseline in Phase 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":257},"commonTop":[]}}}